The upstream stimulatory factor-2a inhibits plasminogen activator inhibitor-1 gene expression by binding to a promoter element adjacent to the hypoxia-inducible factor-1 binding site

Blood

Volumn 97, Issue 9, 2001, Pages 2657-2666

  Samoylenko, Anatoly ^a   Roth, Ulrike ^a   Jungermann, Kurt ^a   Kietzmann, Thomas ^a  

^a Inst fur Biochem/Molek Zellbiol   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA RESPONSE ELEMENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRUVATE KINASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UPSTREAM STIMULATORY FACTOR 2A;

ANIMAL CELL; ARTICLE; BASE PAIRING; BINDING SITE; CARCINOGENESIS; CONTROLLED STUDY; DIMERIZATION; DNA BINDING; DNA FLANKING REGION; GENE CONSTRUCT; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HYPOXIA; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; RAT;

EID: 0035353174     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.9.2657     Document Type: Article

References (60)

1. Lijnen HR, Collen D. Mechanisms of plasminogen activation by mammalian plasminogen activators. Enzyme. 1988;40:90-96.
2. Kruithof EK, Vassalli JD, Schleuning WD, Mattaliano RJ, Bachmann F. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem. 1986;261:11207-11213.
3. Fearns C, Loskutoff DJ. Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide: cellular localization and role of endogenous tumor necrosis factor-alpha. Am J Pathol. 1997;150:579-590.
4. van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem. 1984;259:14914-14921.
5. Erickson LA, Hekman CM, Loskutoff DJ. The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci U S A. 1985;82:8710-8714.
6. Reilly CF, McFall RC. Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem. 1991;266:9419-9427.
7. Busso N, Nicodeme E, Chesne C, Gutilouzo A, Belin D, Hyafil F. Urokinase and type I plasminogen activator inhibitor production by normal human hepatocytes: modulation by inflammatory agents. Hepatology. 1994;20:186-190.
8. Le-Magueresse BB, Pernod G, Kolodie L, Morera AM, Benahmed M. Tumor necrosis factor-alpha regulates plasminogen activator inhibitor-1 in rat testicular peritubular cells. Endocrinology. 1997;138:1097-1105.
9. Heaton JH, Nebes VL, O'Dell LG, Morris SM, Gelehrter TD. Glucocorticoid and cyclic nucleotide regulation of plasminogen activator and plasminogen activator-inhibitor gene expression in primary cultures of rat hepatocytes. Mol Endocrinol. 1989;3:185-192.
10. Podor TJ, Loskutoff DJ. Immunoelectron microscopic localization of type 1 plasminogen activator inhibitor in the extracellular matrix of transforming growth factor-beta-activated endothelial cells. Ann N Y Acad Sci. 1992;667:46-49.
11. Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol. 1990;68:1-19.
12. Carmeliet P, Stassen JM, Schoonjans L, et al. Plasminogen activator inhibitor-1 gene-deficient mice, II: effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest. 1993;92:2756-2760.
13. Eitzman DT, McCoy RD, Zheng X, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest. 1996;97:232-237.
14. Kietzmann T, Roth U, Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood. 1999;94:4177-4185.
15. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995;270:1230-1237.
16. Sawadogo M, Roeder RG. Interaction of a genespecific transcription factor with the adenovirus major late promoter upstream of the TATA box region. Cell. 1985;43:165-175.
17. Murre C, McCaw PS, Baltimore D. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell. 1989;56:777-783.
18. Pognonec P, Roeder RG. Recombinant 43-kDa USF binds to DNA and activates transcription in a manner indistinguishable from that of natural 43/44-kDa USF. Mol Cell Biol. 1991;11:5125-5136.
19. Sirito M, Lin Q, MaityT, Sawadogo M. Ubiquitous expression of the 43- and 44-kDa forms of transcription factor USF in mammalian cells. Nucleic Acids Res. 1994;22:427-433.
20. Viollet B, Lefrancois MA, Henrion A, Kahn A, Raymondjean M, Martinez A. Immunochemical characterization and transacting properties of upstream stimulatory factor isoforms. J Biol Chem. 1996;271:1405-1415.
21. Bruzdzinski CJ, Riordan JM, Nordby EC, Suter SM, Gelehrter TD. Isolation and characterization of the rat plasminogen activator inhibitor-1 gene. J Biol Chem. 1990;265:2078-2085.
22. Cognet M, Bergot MO, Kahn A. cis-acting DNA elements regulating expression of the liver pyruvate kinase gene in hepatocytes and hepatoma cells: evidence for tissue-specific activators and extinguisher. J Biol Chem. 1991;266:7368-7375.
23. Lefrancois-Martinez AM, Martinez A, Antoine B, Raymondjean M, Kahn A. Upstream stimulatory factor proteins are major components of the glucose response complex of the L-type pyruvate kinase gene promoter. J Biol Chem. 1995;270:2640-2643.
24. 2. Biochem J. 1997;321:17-20.
25. Zeheb R, Rafferty UM, Rodriguez MA, Andreasen P, Gelehrter TD. Immunoaffinity purification of HTC rat hepatoma cell plasminogen activator-inhibitor-1. Thromb Haemost. 1987;58:1017-1023.
26. Immenschuh S, Hinke V, Ohlmann A, et al. Transcriptional activation of the haem oxygenase-1 gene by cGMP via a cAMP response element/activator protein-1 element in primary cultures of rat hepatocytes. Biochem J. 1998;334:141-146.
27. Domingo M, Einig C, Eigenbrodt E, Reinacher M. Immunohistological demonstration of pyruvate kinase isoenzyme type L in rat with monoclonal antibodies. J Histochem Cytochem. 1992;40:665-673.
28. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983;11:1475-1489.
29. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12:5447-5454.
30. Johnson MR, Bruzdzinski CJ, Winograd SS, Gelehrter TD. Regulatory sequences and protein-binding sites involved in the expression of the rat plasminogen activator inhibitor-1 gene. J Biol Chem. 1992;267:12202-12210.
31. Bergot MO, Diaz GM, Puzenat N, Raymondjean M, Kahn A. Cis-regulation of the L-type pyruvate kinase gene promoter by glucose, insulin and cyclic AMP. Nucleic Acids Res. 1992;20:1871-1877.
32. Vaulont S, Puzenat N, Kahn A, Raymondjean M. Analysis by cell-free transcription of the liver-specific pyruvate kinase gene promoter. Mol Cell Biol. 1989;9:4409-4415.
33. Boyd KE, Farnham PJ. Myc versus USF: discrimination at the cad gene is determined by core promoter elements. Mol Cell Biol. 1997;17:2529-2537.
34. Boyd KE, Farnham PJ. Coexamination of site-specific transcription factor binding and promoter activity in living cells. Mol Cell Biol. 1999;19:8393-8399.
35. Carter RS, Ordentlich P, Kadesch T. Selective utilization of basic helix-loop-helix-leucine zipper proteins at the immunoglobulin heavy-chain enhancer. Mol Cell Biol. 1997;17:18-23.
36. Takahashi Y, Nakayama K, Itoh S, Fujii-Kuriyama Y, Kamataki T. Inhibition of the transcription of CYP1A1 gene by the upstream stimulatory factor 1 in rabbits: competitive binding of USF1 with AhR.Arnt complex. J Biol Chem. 1997;272:30025-30031.
37. Lun Y, Sawadogo M, Perry M. Autoactivation of Xenopus MyoD transcription and its inhibition by USF. Cell Growth Differ. 1997;8:275-282.
38. Reisman D, Rotter V. The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene. Nucleic Acids Res. 1993;21:345-350.
39. Cogswell JP, Godlevski MM, Bonham M, Bisi J, Babiss L. Upstream stimulatory factor regulates expression of the cell cycle-dependent cyclin B1 gene promoter. Mol Cell Biol. 1995;15:2782-2790.
40. Scholtz B, Kingsley-Kallesen M, Rizzino A. Transcription of the transforming growth factor-beta2 gene is dependent on an E-box located between an essential cAMP response element/activating transcription factor motif and the TATA box of the gene. J Biol Chem. 1996;271:32375-32380.
41. Wang D, Sul HS. Upstream stimulatory factors bind to insulin response sequence of the fatty acid synthase promoter: USF1 is regulated [published erratum appears in J Biol Chem. 1996;271:7873]. J Biol Chem. 1995;270:28716-28722.
42. Vallet VS, Casado M, Henrion AA, et al. Differenrial roles of upstream stimulatory factors 1 and 2 in the transcriptional response of liver genes to glucose. J Biol Chem. 1998;273:20175-20179.
43. White LA, Bruzdzinski CJ, Kutz SM, Gelehrter TD, Higgins PJ. Growth state-dependent binding of USF-1 to a proximal promoter E box element in the rat plasminogen activator inhibitor type 1 gene. Exp Cell Res. 2000;260:127-135.
44. Bendall AJ, Molloy PL. Base preferences for DNA binding by the bHLH-Zip protein USF: effects of MgCl2 on specificity and comparison with binding of Myc family members. Nucleic Acids Res. 1994;22:2801-2810.
45. Chodosh LA, Carthew RW, Morgan JG, Crabtree GR, Sharp PA. The adenovirus major late transcription factor activates the rat gamma-fibrinogen promoter. Science. 1987;238:684-688.
46. Carthew RW, Chodosh LA, Sharp PA. The major late transcription factor binds to and activates the mouse metallothionein I promoter. Genes Dev. 1987;1:973-980.
47. Ribeiro A, Pastier D, Kardassis D, Chambaz J, Cardot P. Cooperative binding of upstream stimulatory factor and hepatic nuclear factor 4 drives the transcription of the human apolipoprotein A-II gene. J Biol Chem. 1999;274:1216-1225.
48. Ghosh AK, Datta PK, Jacob ST. The dual role of helix-loop-helix-zipper protein USF in ribosomal RNA gene transcription in vivo. Oncogene. 1997;14:589-594.
49. Aperlo C, Boulukos KE, Pognonec P. The basic region/helix-loop-helix/leucine repeat transcription factor USF interferes with Ras transformation. Eur J Biochem. 1996;241:249-253.
50. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem. 1996;271:32253-32259.
51. Kallio PJ, Okamoto K, O'Brien S, et al. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J. 1998;17:6573-6586.
52. Luo X, Sawadogo M. Antiproliferative properties of the USF family of helix-loop-helix transcription factors. Proc Natl Acad Sci U S A. 1996;93:1308-1313.
53. Qyang Y, Luo X, Lu T, et al. Cell-type-dependent activity of the ubiquitous transcription factor USF in cellular proliferation and transcriptional activation. Mol Cell Biol. 1999;19:1508-1517.
54. Ismail PM, Lu T, Sawadogo M. Loss of USF transcriptional activity in breast cancer cell lines. Oncogene. 1999;18:5582-5591.
55. Reilly D, Andreseasen P, Duffy MJ. Studies on plasminogen activator inhibitor 1 levels in human breast cancer. Biochem Soc Trans. 1990;18:354-355.
56. Liu G, Shuman MA, Cohen RL. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer. 1995;60:501-506.
57. Pedersen H, Brunner N, Francis D, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 1994;54:4671-4675.
58. Grondahl HJ, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993;53:2513-2521.
59. Kuhn W, Pache L, Schmalfeldt B, et al. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol. 1994;55:401-409.
60. Casado M, Vallet VS, Kahn A, Vaulont S. Essential role in vivo of upstream stimulatory factors for a normal dietary response of the fatty acid synthase gene in the liver. J Biol Chem. 1999;274:2009-2013.